Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
at www.tipranks.com (Thu, 28-May 6:26 AM)
Cognition Therapeutics Charts New Course with Late-Stage Plans for Zervimesine in DLB Psychosis and Alzheimer’s
Market Chameleon (Wed, 1-Apr 11:45 AM)
